| abstract |
A compound of formula I wherein A represents N, CH or CR1; each R 1 independently represents hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, -C (O) -C 1-6 alkyl, -C (O) -C 2-6 alkenyl, -C (O) -alkynyl C2-6, -C (O) -O-C1-6 alkyl, -C (O) -O-C2-6 alkenyl, -C (O) -O-C2-6 alkynyl or phenyl, wherein said phenyl, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl is optionally substituted with one or more substituents selected from halogen, hydroxyl, C1-6 haloalkyl, nitro, C1-6 alkoxy and NR2R3; X represents hydrogen, C1-6 alkyl or -CRaRb-X ', where X' represents a saturated monocyclic moiety having 5-6 ring atoms of which one is N and where one or two additional ring atoms may be a heteroatom selected from N, O and S, which monocyclic ring may be substituted with one or more substituents W, wherein W is selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or (> = O ); Ra and Rb each individually represent hydrogen, -CH3 or halogen; Y represents a heteroaromatic moiety having 5-6 ring atoms, wherein 1-4 of said ring atoms are selected from N, O and S, which heteroaromatic radical can be optionally benzocondensed, and which heteroaromatic radical can be substituted with one or more substituents Z, wherein Z is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cyano, halogen, hydroxy, C1-6 alkoxy, C1-6 haloalkyl and NR2R3; wherein each of R2 and R3 independently represents hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 hydroxyalkyl or C1-6 haloalkyl; each of R4-R8 and R9-R12 independently represents hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, NR2R3, hydroxy, cyano, nitro, C1-6 alkoxy, C1-6 haloalkyl or hydroxyalkyl C1-6; and its pharmaceutically acceptable salts. |